RGNT Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.200

Open

4.010

VWAP

3.95

Vol

230.63K

Mkt Cap

20.20M

Low

3.750

Amount

911.05K

EV/EBITDA(TTM)

--

Total Shares

5.18M

EV

14.02M

EV/OCF(TTM)

--

P/S(TTM)

--

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

Show More

Events Timeline

(ET)

2026-06-17

21:30:00

Regentis Biomaterials Completes $6.5 Million Private Placement

2026-06-17

10:30:00

Regentis Biomaterials Ltd Trading Halted Due to Volatility Trading Pause

2026-04-16 (ET)

2026-04-16

08:40:00

Regentis Biomaterials Collaborates with Humanitas Research Hospital

2026-03-17 (ET)

2026-03-17

09:10:00

Regentis Biomaterials Launches Solvent-Free GelrinC Manufacturing Process

2026-02-19 (ET)

2026-02-19

08:50:00

Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer

News

seekingalpha

06-18seekingalpha

Regentis Biomaterials Raises $6.5 Million in Private Placement

NASDAQ.COM

06-16NASDAQ.COM

Regentis Soars After Withdrawing US Listing Application

stocktwits

06-15stocktwits

Regentis Withdraws Public Offering Proposal Amidst Stock Surge

NASDAQ.COM

06-10NASDAQ.COM

Biotech Companies See Significant Stock Gains

NASDAQ.COM

06-09NASDAQ.COM

Biotech Stocks Show Significant Pre-Market Activity

seekingalpha

02-24seekingalpha

Regentis Biomaterials Financial Overview and IPO Pricing

Valuation Metrics

The current forward P/E ratio for Regentis Biomaterials Ltd (RGNT.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Regentis Biomaterials Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

tomorrow stock gainers

Intellectia · 40 candidates

Volume: >= 1,000,000Price Change Pct: >= $0.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceCrossAboveMA5, PriceCrossAboveMA20One Day Rise Prob: >= 60One Day Predict Return: >= 0.0%

Ticker

Name

Market Cap$

Seagate Technology Holdings PLC

228.44B

Silvercorp Metals Inc

2.69B

Strive Inc

1.23B

Quantum Corp

204.49M

Regentis Biomaterials Ltd

48.69M

MBX Biosciences Inc

1.86B

best penny stocks for day trading tomorrow

Intellectia · 133 candidates

Price: $0.50 - $5.00Volume: >= 1,000,000Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceCrossAboveMA5, PriceCrossAboveMA20

Ticker

Name

Market Cap$

Webuy Global Ltd

5.07M

Xcel Brands Inc

11.51M

Autozi Internet Technology (Global) Ltd

5.14M

Ambitions Enterprise Management Co LLC

32.10M

Paranovus Entertainment Technology Ltd

986.24K

Regentis Biomaterials Ltd

6.63M

Whales Holding RGNT

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regentis Biomaterials Ltd (RGNT) stock price today?

The current price of RGNT is 3.9 USD — it has decreased -6.02

What is Regentis Biomaterials Ltd (RGNT)'s business?

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

What is the price predicton of RGNT Stock?

Wall Street analysts forecast RGNT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regentis Biomaterials Ltd (RGNT)'s revenue for the last quarter?

Regentis Biomaterials Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Regentis Biomaterials Ltd (RGNT)'s earnings per share (EPS) for the last quarter?

Regentis Biomaterials Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Regentis Biomaterials Ltd (RGNT). have?

Regentis Biomaterials Ltd (RGNT) has 0 emplpoyees as of June 30 2026.

What is Regentis Biomaterials Ltd (RGNT) market cap?

Today RGNT has the market capitalization of 20.20M USD.